Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal
Published . Updated .
The Food and Drug Administration (FDA) is announcing the renewal of the Cellular, Tissue, and Gene Therapies Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cellular, Tissue, and Gene Therapies Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 28, 2028, expiration date.
Directly affected
- No company is named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The Food and Drug Administration (FDA) is announcing the renewal of the Cellular, Tissue, and Gene Therapies Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the pub…
Source: Federal Register
How far Acadia Healthcare (ACHC) has moved since 13 Oct 2026
Since the first closing price after “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal,” Acadia Healthcare (ACHC) is -4.55%. The S&P 500 fund (SPY) is -0.40% over the same days, a -4.15% difference versus the market.
Official trades in Acadia Healthcare (ACHC) around 13 Oct 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 14 days before publication, inside 30 days. The filing is listed beside the story “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 32 days before publication, inside 60 days. The filing is listed beside the story “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies mentioned with this story
- ACHC Acadia Healthcare
For “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 13 Oct 2026 story “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 13 Oct 2026 story “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
The 13 Oct 2026 story “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal” names Acadia Healthcare (ACHC) because of this story.
Acadia Healthcare (ACHC) is on the page because GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Ascendis Pharma A/S (ASND) is here too. Its reason reads: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Acadia Healthcare (ACHC)
Dates written in “Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal”: will be in effect until the (28 October 2028).
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
What the saved facts support for Acadia Healthcare (ACHC)
54 out of 100
“Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal” scores 54 out of 100. The score uses 2 sources, and 6 linked companies.